Business Description
Amphastar Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US03209R1032
Description
Amphastar Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the company sells insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has two reportable segments finished pharmaceutical products and API products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.4 | |||||
| Equity-to-Asset | 0.47 | |||||
| Debt-to-Equity | 0.87 | |||||
| Debt-to-EBITDA | 2.79 | |||||
| Interest Coverage | 6.42 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 3.77 | |||||
| Beneish M-Score | -2.46 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 19.5 | |||||
| 3-Year EBITDA Growth Rate | 94.6 | |||||
| 3-Year EPS without NRI Growth Rate | 342.5 | |||||
| 3-Year FCF Growth Rate | 79.1 | |||||
| 3-Year Book Growth Rate | 16.2 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 23.65 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 12 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 31.61 | |||||
| 9-Day RSI | 38.41 | |||||
| 14-Day RSI | 43.2 | |||||
| 6-1 Month Momentum % | 9.33 | |||||
| 12-1 Month Momentum % | -1.17 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.43 | |||||
| Quick Ratio | 2.61 | |||||
| Cash Ratio | 1.58 | |||||
| Days Inventory | 125.32 | |||||
| Days Sales Outstanding | 64.88 | |||||
| Days Payable | 98.4 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -0.4 | |||||
| Shareholder Yield % | -14.09 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 52.98 | |||||
| Operating Margin % | 29.61 | |||||
| Net Margin % | 21.8 | |||||
| FCF Margin % | 24.93 | |||||
| ROE % | 23.56 | |||||
| ROA % | 10.28 | |||||
| ROIC % | 16.97 | |||||
| 3-Year ROIIC % | 26.04 | |||||
| ROC (Joel Greenblatt) % | 56.08 | |||||
| ROCE % | 15.98 | |||||
| Years of Profitability over Past 10-Year | 7 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 17.05 | |||||
| Forward PE Ratio | 11.54 | |||||
| PE Ratio without NRI | 13.31 | |||||
| Shiller PE Ratio | 61.51 | |||||
| Price-to-Owner-Earnings | 16.66 | |||||
| PEG Ratio | 0.17 | |||||
| PS Ratio | 3.87 | |||||
| PB Ratio | 3.59 | |||||
| Price-to-Tangible-Book | 17.18 | |||||
| Price-to-Free-Cash-Flow | 15.86 | |||||
| Price-to-Operating-Cash-Flow | 13.3 | |||||
| EV-to-EBIT | 10.92 | |||||
| EV-to-EBITDA | 8.89 | |||||
| EV-to-Revenue | 3.73 | |||||
| EV-to-FCF | 16.93 | |||||
| Price-to-Projected-FCF | 1.57 | |||||
| Price-to-Median-PS-Value | 1.11 | |||||
| Price-to-Peter-Lynch-Fair-Value | 0.46 | |||||
| Price-to-Graham-Number | 3.05 | |||||
| Earnings Yield (Greenblatt) % | 9.16 | |||||
| FCF Yield % | 7.85 | |||||
| Forward Rate of Return (Yacktman) % | 22.98 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Amphastar Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 663.139 | ||
| EPS (TTM) (€) | 2.75 | ||
| Beta | 0.55 | ||
| Volatility % | 34.29 | ||
| 14-Day RSI | 43.2 | ||
| 14-Day ATR (€) | 1.65983 | ||
| 20-Day SMA (€) | 45.7255 | ||
| 12-1 Month Momentum % | -1.17 | ||
| 52-Week Range (€) | 33.35 - 57 | ||
| Shares Outstanding (Mil) | 48.37 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Amphastar Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Amphastar Pharmaceuticals Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Amphastar Pharmaceuticals Inc Frequently Asked Questions
What is Amphastar Pharmaceuticals Inc(STU:29A)'s stock price today?
The current price of STU:29A is €43.12. The 52 week high of STU:29A is €57.00 and 52 week low is €33.35.
When is next earnings date of Amphastar Pharmaceuticals Inc(STU:29A)?
The next earnings date of Amphastar Pharmaceuticals Inc(STU:29A) is 2025-02-28 Est..
Does Amphastar Pharmaceuticals Inc(STU:29A) pay dividends? If so, how much?
Amphastar Pharmaceuticals Inc(STU:29A) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers